Stock Code ：**1762**

中化合成 CENRA+ API Solutions

Second Quarter 2025 Investor Conference

2025/8/25

中化合成
CENRA•API Solutions

Safe Harbor Notice

- **CCSB's presentation contains forward-looking statements subject to significant risks and uncertainties. Actual results may differ materially from those contained in the forward-looking statements.**

- **The forward-looking statements in this release reflect the current belief of CCSB as of the date of this release. We undertake no obligation to update these forward-looking statements for new information, future events or otherwise.**

中化合成
CENRA•API Solutions

Company

- **Stock Code:1762**
- **Employee: 270 (As of 2025/6/30)**
- **2025 /1/1-6/30 Revenue 0.5 billion**

- **Brief History**
- **Founded in 1964**
  - ✓ The first registered and one of the largest bulk pharmaceutical chemical manufacturers in Taiwan
  - ✓ First FDA-approved plant (1984) in Taiwan
- **Turning Points**
  - ✓ Formed the New Management Team in 1997, and established 4 cGMP Production Lines for Synthetic Products and 2 cGMP Production Lines for Biotechnology Products
  - ✓ Established US Sales Office: Pharmaports in 2000
  - ✓ Initial public offering on December 20, 2010

中化合成
CENRA•API Solutions

Key Strengths

- An API factory with bio-fermentation and chemical synthesis technology and equipment.
- Ensure compliance with and successfully pass inspections by the US FDA and European PIC/S regulations.
- With certified API master file DMFs for a variety of products, our export products are competitive.
- From small batch research and development to mass production of APIs, offering comprehensive one-stop services.

中化合成
CENRA•API Solutions

US DMF List

17399 •RAPAMYCIN	18494 •MYCOPHENOLATE MOFETIL USP	18985 •TACROLIMUS	23213 •TACROLIMUS SD20	24372 •MYCOPHENOLATE MOFETIL HYDROCHLORIDE ANHYDROUS	26271 •ETHYL ICOSAPENTATE
26819 •EVEROLIMUS PRE-MIX USP	27216 •EVEROLIMUS USP	27585 •CASPOFUNGIN ACETATE	31189 •RAPAMYCIN (SIROLIMUS)	33333 •MYCOPHENOLATE MOFETIL USP (PROCESS B)	35848 •MYCOPHENOLATE SODIUM USP
36030 •BARICITINIB	36174 •RIBOCICLIB SUCCINATE	36640 •MIDOSTAURIN	37532 •TOFACITINIB CITRATE	37586 •PALBOCICLIB	37597 •OZANIMOD HYDROCHLORIDE
38111 •EVEROLIMUS B02 USP	38310 •TACROLIMUS (PROCESS B)	38511 •DIFELIKEFALIN ACETATE	39312 •ESLICARBAZEPINE ACETATE	40868 • ELTROMBOPAG OLAMINE	41490 • SETMELANOTIDE ACETATE
	41491 • BRIVARACETAM	41492 • SELUMETINIB SULFATE	41493 • PLECANATIDE	41494 • TRILACICLIB DIHYDROCHLORIDE	

中化合成
CENRA•API Solutions

Key Products

- Active Pharmaceutical Ingredients (API) for branded drugs and generic drugs
  - Everolimus: It is used for an anticancer drug, cardiovascular stent coating and immunosuppressive applications.
  - Ethyl Icosapentate: Used for triglyceride-lowering medication.
  - Caspofungin Acetate: An echinocandin antifungal drug.
  - Rapamycin: An immunosuppressive agent also used in cancer therapy and as a coating for cardiovascular drug-eluting stents (DES).
  - Tacrolimus: An immunosuppressive agent, also used topically to treat autoimmune skin diseases such as atopic dermatitis.

中化合成
CENRA•API Solutions

Consolidated Comprehensive Income Statement

Amount: NT$ Thousand

Item \ Year	2025/1/1-6/30	
	Amount	%
Net Sales	536,991	100
Gross Profit	89,751	17
Operating Profit	(68,148)	(12)
Profit before Tax	(71,898)	(13)
Net Profit	(60,014)	(11)
Basic EPS(NT$)	(1.08)	


中化合成
CENRA•API Solutions

2025/1/1-6/30 Sales Distribution By Region

Region/ Product	%	EPAE	EVE	FK506	MMF	RAPA	CAS
US	35	●	●		●	●	
Asia	16		●	●		●	
Europe	45		●			●	●
Taiwan	4			●			

中化合成
CENRA•API Solutions

Share of Revenue by Key Products



中化合成
CENRA•API Solutions

Latest News

Capacity

- Invested in new equipment to enhance the product competitiveness of Everolimus.
- Completed procurement of equipment necessary for the production of the semi-recombinant Semaglutide API and initiated preparations for process validation.

Regulatory


- Submitted the US DMF application for Setmelanotide acetate, Brivaracetam, Selumetinib sulfate, Plecanatide, and Trilaciclib 2HCl.
- Successfully passed customers' on-site inspections from the US, Japan, and Europe.

ESG

- Continue providing care for the elderly in the community this year , while continuing to implement ESG social care initiatives.
- Awarded the EcoVadis Bronze Medal, ranking in the top 35% for sustainability performance on the ESG platform.

中化合成
CENRA+API Solutions

Future Outlook (1/2)



- With the expansion of EVE production capacity, market penetration is expected to gradually increase.
- Upon completion of SG process validation, efforts will focus on entering the diabetes treatment and weight loss markets, thereby broadening the product portfolio.
- Registration approvals and regulatory change operations are conducted in multiple countries, with the goal of continuously expanding into new markets.
- Short-term increase of revenue from CDMO/CMO. Develop drug substances in advance and engage in international new drug R&D collaborations.

中化合成
CENRA•API Solutions

Future Outlook(2/2)


P4 & P3 Products (expected launch in 5-10 years)

- CKD-Associated Pruritus
  Difelikefalin Acetate
- Multiple Sclerosis
  Ozanimod HCl
- Genetic Obesity
  Setmelanotide Acetate
- SCLC Myelopreservation Therapy
  Trilaciclib 2HCl
- Diabetes,Type 2, Cardiovascular Risk Reduction, Weight Loss
  Semaglutide

P3 Products (expected launch in 3-5 years)

- Epilepsy, Seizures
  Eslicarbazepine Acetate, Brivaracetam
- Neurofibromatosis Type 1
  Selumetinib Sulfate
- Hematology
  Eltrombopag Olamine
- Breast Cancer
  Palbociclib, Ribociclib Succinate
- Rheumatoid Arthritis
  Baricitinib, Tofacitinib Citrate

◆ Development Milestones



中化合成
CENRA•API Solutions

List of Abbreviations

Abbreviation	Full names	Treatments/Indications
CAS	Caspofungin Acetate	Antifungal
ELT	Eltrombopag Olamine	Hematology
ESL	Eslicarbazepine Acetate	Epilepsy, Seizures
EPAE	Ethyl Icosapentate	Hypertriglyceridemia, Cardiovascular Risk Reduction
EVE	Everolimus	Renal Cell Carcinoma, Breast Cancer, Neuroendocrine Carcinoma, Organ Transplant, Rejection Prophylaxis
MMF	Mycophenolate Mofetil	Organ Transplant, Rejection Prophylaxis
MPA-NA	Mycophenolate Sodium	Immunosuppressant
RAPA	Rapamycin (Sirolimus)	Immunosuppressant, Organ Transplant, Rejection Prophylaxis
SET	Setmelanotide Acetate	Genetic Obesity
FK506	Tacrolimus	Organ Transplant, Rejection Prophylaxis
SG	Semaglutide	Diabetes, Type 2, Cardiovascular Risk Reduction, Weight Loss

中化合成
CENRA+API Solutions

Always a Team Player







http://www.ccsb.com.tw

Stock Code ：1762